Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy
- 26 March 2024
- journal article
- research article
- Published by Elsevier in Clinical Oncology
- Vol. 36 (7) , 402-405
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Single-Fraction Stereotactic Ablative Body Radiotherapy for Primary and Extracranial Oligometastatic CancersClinical Oncology, 2023
- Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With CancerJAMA Oncology, 2022
- The Management of Oligometastases in Non-small Cell Lung Cancer – is Stereotactic Ablative Radiotherapy now Standard of Care?Clinical Oncology, 2022
- Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2022
- Should We be Offering Our Patients With Oligometastases Stereotactic Ablative Body Radiotherapy?Clinical Oncology, 2021
- Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy – NoClinical Oncology, 2021
- Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases—A Phase 2 Randomized Controlled Trial Within a Prospective CohortInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerJAMA Oncology, 2020
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerJAMA Oncology, 2017